This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

EPAM, Synacor Are Class of IPO Calendar

Stocks in this article: EPAM SYNC

NEW YORK ( TheStreet -- Despite all the hype from the Facebook filing, 2012 is off to a slow start when it comes to IPO activity.

According to Renaissance Capital, only 8 IPOs have priced so far in the U.S. and just $800 million in proceeds have been raised. This week, 12 offerings are still on the docket after Erickson Air-Crane postponed.

Unfortunately, this looks like a case of quantity over quality and there's a lot to avoid. Caesars Entertainment (CZR) didn't exactly get off to a promising start when it delayed its pricing on Monday, citing a "technical glitch."

The casino operator was able to pull off the pricing on Tuesday though, raising $16 million through the sale of 1.8 million shares at $9 each, the midpoint of its range. This one looks like a real gamble as the company is highly leveraged and will probably use new shareholder money to relieve some of debt pressure.

Caesars isn't the only dodgy offering this week, Ceres (CERE) is a close second. It's a biotech agriculture company that uses crops to generate fuel. The only problem is that the government is beginning to extract itself out of the energy crop subsidy business.

Plus Ceres competes against giants like Dow Chemical (DOW) and Monsanto (MON). Ceres is hoping to raise $110 million on Thursday, seeking to sell 5 million shares at $21 to $23 each. Then there's GSE Holdings (GSE), which tried to go public last year and postponed as the IPO market ground to a halt. GSE makes plastic membrane covers for use at garbage dumps and mines. It's a loss maker that's looking to sell 7 million shares at between $8 to $10 each, aiming to raise $63 million by Friday.

Cancer drug developers are a hot IPO trend so far this year and the current week brings two more to the market. ChemoCentryx (CCXI) is a biopharma company focused on discovering, developing and then commercializing drugs to treat autoimmune diseases and cancer.

Its hook is small molecule targeting, and the company wants to raise $60 million for further clinical testing. It's offering 4 million shares with a pricing range of $14 to $16 per share. A price-to-sales ratio of 68.3X (at the midpoint of the range) for a company with no products seems expensive.

TVAX Biomedical (TVAX) is looking for $20 million from the market in order to fund its clinical trials too but it's really too small for retail investors to bother with.

Roundy's Parent (RNDY)is the largest offering of the week, and it priced on Tuesday, reportedly selling 19.2 million shares at $8.50 each, raising $163 million.

A grocery store chain based in the Midwest, Roundy's sold more stock than expected but at a lower price compared to a projected range of $10-$12 each. It had been looking to bring in $200 million. Roundy's has good cash flow and says it plans to pay a hefty 8.4% dividend.

IPO Desktop President Francis Gaskins warns investors not to get sucked into those promises. "In order to pay that dividend, Roundy's would have to pay out 73% of its net income, leaving little room for growth capital," said Gaskins. He also points out that its competitors Safeway (SWY) and Kroger (KR) only pay out 36% of their earnings.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,907.10 +102.30 0.57%
S&P 500 2,073.58 +2.93 0.14%
NASDAQ 4,777.5270 +12.1470 0.25%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs